Molyneux Medico-Legal And Consulting Ltd 08931894 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is the provision of neuroradiology consultancy services. Digita Accounts Production Advanced 6.30.9574.0 true 08931894 2025-04-01 2026-03-31 08931894 2026-03-31 08931894 bus:OrdinaryShareClass1 2026-03-31 08931894 bus:OrdinaryShareClass2 2026-03-31 08931894 bus:OrdinaryShareClass3 2026-03-31 08931894 bus:OrdinaryShareClass4 2026-03-31 08931894 bus:OrdinaryShareClass5 2026-03-31 08931894 core:RetainedEarningsAccumulatedLosses 2026-03-31 08931894 core:ShareCapital 2026-03-31 08931894 core:CurrentFinancialInstruments 2026-03-31 08931894 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 08931894 core:Goodwill 2026-03-31 08931894 core:FurnitureFittingsToolsEquipment 2026-03-31 08931894 core:MotorVehicles 2026-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2026-03-31 08931894 core:OtherRelatedParties 2026-03-31 08931894 bus:SmallEntities 2025-04-01 2026-03-31 08931894 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 08931894 bus:FilletedAccounts 2025-04-01 2026-03-31 08931894 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 08931894 bus:RegisteredOffice 2025-04-01 2026-03-31 08931894 bus:Director1 2025-04-01 2026-03-31 08931894 bus:Director2 2025-04-01 2026-03-31 08931894 bus:Director3 2025-04-01 2026-03-31 08931894 bus:Director5 2025-04-01 2026-03-31 08931894 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 08931894 bus:OrdinaryShareClass2 2025-04-01 2026-03-31 08931894 bus:OrdinaryShareClass3 2025-04-01 2026-03-31 08931894 bus:OrdinaryShareClass4 2025-04-01 2026-03-31 08931894 bus:OrdinaryShareClass5 2025-04-01 2026-03-31 08931894 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 08931894 bus:Agent1 2025-04-01 2026-03-31 08931894 core:Goodwill 2025-04-01 2026-03-31 08931894 core:FurnitureFittings 2025-04-01 2026-03-31 08931894 core:FurnitureFittingsToolsEquipment 2025-04-01 2026-03-31 08931894 core:MotorVehicles 2025-04-01 2026-03-31 08931894 core:OfficeEquipment 2025-04-01 2026-03-31 08931894 core:KeyManagementPersonnel 2025-04-01 2026-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-04-01 2026-03-31 08931894 core:OtherRelatedParties 2025-04-01 2026-03-31 08931894 countries:EnglandWales 2025-04-01 2026-03-31 08931894 2025-03-31 08931894 core:Goodwill 2025-03-31 08931894 core:FurnitureFittingsToolsEquipment 2025-03-31 08931894 core:MotorVehicles 2025-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-03-31 08931894 core:OtherRelatedParties 2025-03-31 08931894 2024-04-01 2025-03-31 08931894 2025-03-31 08931894 bus:OrdinaryShareClass1 2025-03-31 08931894 bus:OrdinaryShareClass2 2025-03-31 08931894 bus:OrdinaryShareClass3 2025-03-31 08931894 bus:OrdinaryShareClass4 2025-03-31 08931894 bus:OrdinaryShareClass5 2025-03-31 08931894 core:RetainedEarningsAccumulatedLosses 2025-03-31 08931894 core:ShareCapital 2025-03-31 08931894 core:CurrentFinancialInstruments 2025-03-31 08931894 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 08931894 core:Goodwill 2025-03-31 08931894 core:FurnitureFittingsToolsEquipment 2025-03-31 08931894 core:MotorVehicles 2025-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2025-03-31 08931894 core:OtherRelatedParties 2025-03-31 08931894 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 08931894 bus:OrdinaryShareClass2 2024-04-01 2025-03-31 08931894 bus:OrdinaryShareClass3 2024-04-01 2025-03-31 08931894 bus:OrdinaryShareClass4 2024-04-01 2025-03-31 08931894 bus:OrdinaryShareClass5 2024-04-01 2025-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-04-01 2025-03-31 08931894 core:OtherRelatedParties 2024-04-01 2025-03-31 08931894 2024-03-31 08931894 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2024-03-31 08931894 core:OtherRelatedParties 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08931894

Molyneux Medico-Legal And Consulting Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 31 March 2026

 

Molyneux Medico-Legal And Consulting Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Financial Statements

4 to 9

 

Molyneux Medico-Legal And Consulting Ltd

Company Information

Directors

Dr A J Molyneux

Dr A J Molyneux

Miss C A Morris

Mr D C A Molyneux

Registered office

Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR

Accountants

Tax Innovations Limited Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR

 

Molyneux Medico-Legal And Consulting Ltd

(Registration number: 08931894)
Balance Sheet as at 31 March 2026

Note

2026
£

2025
£

Fixed assets

 

Intangible assets

4

19,797

26,396

Tangible assets

5

34,323

43,003

 

54,120

69,399

Current assets

 

Debtors

6

70,400

57,047

Cash at bank and in hand

 

13,435

6,313

 

83,835

63,360

Creditors: Amounts falling due within one year

7

(5,896)

(2,901)

Net current assets

 

77,939

60,459

Net assets

 

132,059

129,858

Capital and reserves

 

Called up share capital

8

80

80

Retained earnings

131,979

129,778

Shareholders' funds

 

132,059

129,858

 

Molyneux Medico-Legal And Consulting Ltd

(Registration number: 08931894)
Balance Sheet as at 31 March 2026

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

•

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 14 October 2026 and signed on its behalf by:
 

.........................................
Dr A J Molyneux
Director

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Innovations House
19 Staple Gardens
Winchester
Hampshire
SO23 8SR
United Kingdom


 

The principal place of business is:
3 Walnut Close
Wootton
Woodstock
OX20 1DA

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
- the amount of revenue can be reliably measured;
- it is probable that future economic benefits will flow to the entity; and
- specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixture and fittings

25% straight line

Office equipment

33% straight line

Motor vehicle

20% reducing balance

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight line basis over 15 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 4 (2025 - 4).

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

4

Intangible assets

Goodwill
 £

Total
£

Cost or valuation

At 1 April 2025

98,985

98,985

At 31 March 2026

98,985

98,985

Amortisation

At 1 April 2025

72,589

72,589

Amortisation charge

6,599

6,599

At 31 March 2026

79,188

79,188

Carrying amount

At 31 March 2026

19,797

19,797

At 31 March 2025

26,396

26,396

5

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 April 2025

18,707

71,853

90,560

Additions

375

-

375

At 31 March 2026

19,082

71,853

90,935

Depreciation

At 1 April 2025

17,643

29,914

47,557

Charge for the year

667

8,388

9,055

At 31 March 2026

18,310

38,302

56,612

Carrying amount

At 31 March 2026

772

33,551

34,323

At 31 March 2025

1,064

41,939

43,003

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

6

Debtors

Current

Note

2026
£

2025
£

Trade debtors

 

22,250

21,320

Amounts owed by related parties

10

38,553

27,744

Other debtors

 

9,597

7,983

   

70,400

57,047

7

Creditors

Creditors: amounts falling due within one year

2026
£

2025
£

Due within one year

Taxation and social security

2,995

-

Accruals and deferred income

2,901

2,901

5,896

2,901

8

Share capital

Allotted, called up and fully paid shares

2026

2025

No.

£

No.

£

Ordinary A Shares of £1 each

34

34

34

34

Ordinary B Shares of £1 each

34

34

34

34

Ordinary C Shares of £1 each

4

4

4

4

Ordinary D Shares of £1 each

4

4

4

4

Ordinary E Shares of £1 each

4

4

4

4

80

80

80

80

 

Molyneux Medico-Legal And Consulting Ltd

Notes to the Financial Statements for the Year Ended 31 March 2026

9

Dividends

Interim dividends paid

2026
£

2025
£

Interim dividend of £147.06 (2025 - £410.67) per each Ordinary A Shares

5,000

13,963

Interim dividend of £Nil per each Ordinary B Shares

-

-

Interim dividend of £Nil per each Ordinary C Shares

-

-

Interim dividend of £Nil per each Ordinary D Shares

-

-

Interim dividend of £Nil per each Ordinary E Shares

-

-

5,000

13,963

10

Related party transactions

Loans to related parties

2026

Key management
£

Other related parties
£

Total
£

At start of period

-

27,744

27,744

Advanced

9,597

10,000

19,597

Interest transactions

-

809

809

At end of period

9,597

38,553

48,150

2025

Key management
£

Other related parties
£

Total
£

At start of period

30,117

-

30,117

Advanced

-

27,000

27,000

Repaid

(30,117)

-

(30,117)

Interest transactions

-

744

744

At end of period

-

27,744

27,744

Terms of loans to related parties

Key management loan to directors are on a non fixed repayment basis with 0% interest charged
 Other related party loan provided to Oxford Neurophysiology Ltd (Director: Mr Adam Molyneux); Interest to be charges at the Bank of England base rate less 1%; no fixed repayment period.